Literature DB >> 15937338

A novel polymorphic cytochrome P450 formed by splicing of CYP3A7 and the pseudogene CYP3AP1.

Cristina Rodriguez-Antona1, Magnus Axelson, Charlotta Otter, Anders Rane, Magnus Ingelman-Sundberg.   

Abstract

The cytochrome P450 3A7 (CYP3A7) is the most abundant CYP in human liver during fetal development and first months of postnatal age, playing an important role in the metabolism of endogenous hormones, drugs, differentiation factors, and potentially toxic and teratogenic substrates. Here we describe and characterize a novel enzyme, CYP3A7.1L, encompassing the CYP3A7.1 protein with the last four carboxyl-terminal amino acids replaced by a unique sequence of 36 amino acids, generated by splicing of CYP3A7 with CYP3AP1 RNA. The corresponding CYP3A7-3AP1 mRNA had a significant expression in liver, kidney, and gastrointestinal tract, and its presence was found to be tissue-specific and dependent on the developmental stage. Heterologous expression in yeast revealed that CYP3A7.1L was a functional enzyme with a specific activity similar to that of CYP3A7.1 and, in some conditions, a different hydroxylation specificity than CYP3A7.1 using dehydroepiandrosterone as a substrate. CYP3A7.1L was found to be polymorphic due to a mutation at position -6 of the first splicing site of CYP3AP1 (CYP3A7_39256T-->A), which abrogates the pseudogene splicing. This polymorphism had pronounced interethnic differences and was in linkage disequilibrium with other functional polymorphisms described in the CYP3A locus: CYP3A7*2 and CYP3A5*1. Therefore, the resulting CYP3A haplotypes express different sets of enzymes within the population. In conclusion, a novel mechanism, consisting of the splicing of the pseudogene CYP3AP1 to CYP3A7, causes the formation of the novel CYP3A7.1L having a different tissue distribution and functional properties than the parent CYP3A7 enzyme, with possible developmental, physiological, and toxicological consequences.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15937338     DOI: 10.1074/jbc.M502309200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  6 in total

Review 1.  Pharmacogenetics of drug-metabolizing enzymes: implications for a safer and more effective drug therapy.

Authors:  Magnus Ingelman-Sundberg; Cristina Rodriguez-Antona
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2005-08-29       Impact factor: 6.237

2.  The influence of CYP3A5 genotype on dexamethasone induction of CYP3A activity in African Americans.

Authors:  Patrick J Roberts; Kristan D Rollins; Angela D M Kashuba; Mary F Paine; Andrew C Nelsen; Eric E Williams; Cassandra Moran; Jatinder K Lamba; Erin G Schuetz; Roy L Hawke
Journal:  Drug Metab Dispos       Date:  2008-05-19       Impact factor: 3.922

3.  Fluticasone propionate pharmacogenetics: CYP3A4*22 polymorphism and pediatric asthma control.

Authors:  Chris Stockmann; Bernhard Fassl; Roger Gaedigk; Flory Nkoy; Derek A Uchida; Steven Monson; Christopher A Reilly; J Steven Leeder; Garold S Yost; Robert M Ward
Journal:  J Pediatr       Date:  2013-01-03       Impact factor: 4.406

4.  Role of Chromatin Structural Changes in Regulating Human CYP3A Ontogeny.

Authors:  Nicholas L Giebel; Jeffrey D Shadley; D Gail McCarver; Kenneth Dorko; Roberto Gramignoli; Stephen C Strom; Ke Yan; Pippa M Simpson; Ronald N Hines
Journal:  Drug Metab Dispos       Date:  2016-02-26       Impact factor: 3.922

Review 5.  Neonatal cytochrome P450 CYP3A7: A comprehensive review of its role in development, disease, and xenobiotic metabolism.

Authors:  Haixing Li; Jed N Lampe
Journal:  Arch Biochem Biophys       Date:  2019-08-22       Impact factor: 4.013

Review 6.  Pseudogenes and Liquid Phase Separation in Epigenetic Expression.

Authors:  Bernard Nsengimana; Faiz Ali Khan; Usman Ayub Awan; Dandan Wang; Na Fang; Wenqiang Wei; Weijuan Zhang; Shaoping Ji
Journal:  Front Oncol       Date:  2022-07-08       Impact factor: 5.738

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.